This review highlights the importance of patient compliance in lifelong antihypertensive therapy and discusses the benefits of combination therapy alongside the risks of polypharmacy.
Answers are grounded in this paper and cite their sources.
Patient compliance with lifelong hypertension therapy remains problematic; leaves open optimal strategies to balance combination benefits against interaction risks in polypharmacy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ondřej Ludka (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: